Building the intelligence layer for modern biotech
Contraview is developing ContraNova, an intelligent system that turns the noise of science into clear signals for action. We read papers, trials, patents, markets and company data so the AI can see where the field is moving and why it matters.
what we do
AI powered biotech intelligence
ContraNova brings clarity to how science becomes investment. The platform continuously analyzes publications, clinical evidence, patents and operating data to surface technologies that are actually moving the field forward. It gives investors and research leaders a clean view of what is working, what is slowing down and where value is forming.
The system learns from every new datapoint and validates against real outcomes. By combining predictive modeling with domain grounded reasoning, ContraNova helps capital flow to the discoveries that matter. The goal is a more open, efficient and evidence based biotech ecosystem.
our technology
How the engine works
ContraNova combines large language models, knowledge graphs and curated scientific datasets to reason across biology, clinical evidence and markets at once. Each model offers a different perspective and the system reconciles them into a single, transparent view.
The architecture is modular and always learning. As new research, trials or IP appear, the system updates its understanding and explains the drivers behind a shift. Inside the team we are also preparing a safe sandbox where we can test frontier reasoning systems on synthetic biotech tasks before they touch real decisions.
Embracing AI's Scale
Advanced AI-driven Analysis
ContraNova scores every biotech company on its odds of being acquired. In a backtest on 2019 to 2022, companies it ranked in the top 10% were acquired for $100M or more within three years at nearly 3x the base rate (AUC 0.74), using only information public at the time.
Comprehensive Market Intelligence
One system covers 24,000+ companies, public and private, from seed to big pharma: 37,000+ drug programmes, 76,000 clinical trials, 80,000 financing and deal records back to 1980, and 44,000 executives, founders and board members.
Time and Resource Efficiency
The engine tracks 2,800 variables per company and refreshes them every night. Questions that used to take an analyst a week of reading come back in minutes, with every number tied to its source.
Specialized Databases for Precision
ContraNova reads at evidence level, not headline level: 187,000 scientific papers, 7,500 drug targets, 274,000 searchable passages of trial, programme and company text, and 328,000 drug-versus-control effect results from clinical trials. Each result stays tied to the trial arm and timepoint where it was measured.
Insights for Informed Decision-Making
Every score ships with its evidence: the inputs that moved it, how much data sits behind it, and what is missing. Our acquisition model holds up from 12 to 36 months in tests on years it never saw, and no model is served until it passes a leak audit.
Competitive Edge
Most tools show what already happened. ContraNova is built to show what happens next: who reads out first, which mechanisms have failed before, and who is likely to buy. It is used day to day on live venture deals, and we are building it with funds.
What our clients say
“Companies can use AI internally to enhance business operations such as procurement. A data unification software, uses machine learning to clean, analyze, and sort procurement data.”
Paul Schwimmer
CEO @ Precision Immunology Institute, USA
“Companies can use AI internally to enhance business operations such as procurement. A data unification software, uses machine learning to clean, analyze, and sort procurement data.”
Paul Schwimmer
CEO @ Precision Immunology Institute, USA
Subscribe to our newsletter
Receive our latest news, content, and upcoming events
We promise no spam; you’ll receive quarterly downloads of our updates as well as press releases.
I agree to the Terms of Service